Melanoma breakthrough - neoadjuvant treatment saving lives.

Melanoma breakthrough - neoadjuvant treatment saving lives.

9 February 2021

In what is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy, a new study has revealed that drug treatment before surgery is effective in preventing deadly spread of the disease.


The study, published today in the prestigious journal Nature Medicine, pooled data from six clinical trials where drug therapy was given before surgery, known as neoadjuvant therapy.

Researchers found that giving Stage III patients a short course of pre-operative targeted or immunotherapy was effective, and the stronger a patient’s response to that treatment in the first six to nine weeks, the greater the likelihood their disease would not recur after surgery.

Remarkably, in the 75% of patients who responded well to dual immunotherapy given before surgery, only 3% saw their tumours return after surgery, suggesting that 97% will likely be cured.

‘The neoadjuvant approach is a new way of dealing with melanoma and is a game changer for Stage III patients with bulky disease which has spread to their lymph nodes,’ said Professor Georgina Long AO, Melanoma Institute Australia (MIA) Co-Medical Director and study senior author.

‘We have flipped the ‘surgery then drugs’ rationale on its head. By utilising our arsenal of ground-breaking new treatments before surgical removal of the tumours, this approach is proving effective in stopping melanoma in its tracks and preventing its recurrence and spread to distant organs.’

Data from the study suggests that immunotherapy may work more effectively when given before, rather than after surgery, due to the presence of the bulky tumour provoking an immune response. The concept is similar to sniffer dogs being trained by exposure to illegal drugs – if they know what they’re searching for, the more effective they are at detection.

In addition to training the immune system to work more effectively against melanoma, neoadjuvant therapy also enables a clinician to assess early on if a patient is responding to a particular treatment and decide on an alternative plan if needed. It can also make surgery less complex.

Associate Professor Alex Menzies, MIA Oncologist and study first author, said; ‘Although neoadjuvant therapy for Stage III patients is not currently an approved standard of treatment, we anticipate that this will ultimately change following the very promising clinical trial results.’

The currently approved schedule is to first surgically remove the melanoma tumours, and then give targeted or immunotherapy post-operatively (known as adjuvant therapy). This approach halves the risk of melanoma recurrence. However it’s impossible to tell on an individual level whether the drug treatment is working.

‘This study shows that giving drug therapy before surgery reduces risk of recurrence even further, preventing spread to vital organs like the brain and liver and saving more lives. We can also now tell whether the drugs are working for an individual patient, so we can direct subsequent treatment and follow-up accordingly,’ Associate Professor Menzies said.

Professor Long added: ‘This early marker of a patient’s response to treatment should be considered a new benchmark for rapid drug development in melanoma. It is also a great platform to help fast track laboratory research to understand why some patients do not respond to treatment.’

Melanoma Institute Australia has been instrumental in trialling neoadjuvant drug therapy and is a foundation member of the International Neoadjuvant Melanoma Consortium (INMC).
This study is the first large analysis of immunotherapy in the neoadjuvant setting in any cancer, results of which should pave the way for the use of immunotherapy pre-operatively in many other cancer types.

Australia has the highest melanoma rates in the world with one person diagnosed every 30 minutes, and it is estimated 1300 people will die from the disease in Australia this year.

This latest research has focussed on patients with earlier stage melanoma (Stage III), and how to prevent their disease from progressing to advanced melanoma. The study will also assist with the transition of drug development into the neoadjuvant setting rather than the increasingly complex and inefficient metastatic setting.

‘Treatment for advanced melanoma patients, where their disease has metastasised and spread to distant organs, has come a long way in the last decade,’ said Professor Richard Scolyer, MIA Co-Medical Director.
‘It is exciting that patients with earlier stage disease are now also benefiting from research breakthroughs. If we can prevent these patients from progressing to Stage IV or metastatic disease, then we will be even closer to achieving our goal of zero deaths from melanoma.’


Read the paper in Nature Medicine: 
'Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)’

Alexander M. Menzies, Rodabe N. Amaria, Elisa A. Rozeman, Alexander C. Huang, Michael T. Tetzlaff, Bart A. van de Wiel, Serigne Lo, Ahmad A. Tarhini, Elizabeth M. Burton, Thomas E. Pennington, Robyn P. M. Saw, Xiaowei Xu, Giorgos C. Karakousis, Paolo A. Ascierto, Andrew J. Spillane, Alexander C. J. van Akkooi, Michael A. Davies, Tara C. Mitchell, Hussein A. Tawbi, Richard A. Scolyer, Jennifer A. Wargo, Christian U. Blank & Georgina V. Long. Nat Med (2021). 


For media enquiries, please contact:
Jennifer Durante |Melanoma Institute Australia | 0412 798 990 | jennifer.durante@melanoma.org.au

Australasian Melanoma Conference AMC2021
19 Nov - 20 Nov 2021

Australasian Melanoma Conference AMC2021

The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.

Australian researchers spearhead paradigm shift in melanoma treatment
20 Sep 2021

Australian researchers spearhead paradigm shift in melanoma treatment

Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread

Tags: melanoma
Melanoma March physical events in 2022
20 Sep 2021

Melanoma March physical events in 2022

We are excited to announce a return to our much-loved physical Melanoma March events in March 2022! 

Tags: melanoma
Melanoma Bike Bash 2021: What a ride!
20 Sep 2021

Melanoma Bike Bash 2021: What a ride!

Over two fun, yet challenging, days in September an intrepid group of riders and crew successfully completed the annual Melanoma Bike Bash in WA!

Tags: melanoma
Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS
16 Sep 2021

Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS

Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.

Tags: melanoma
MIA researchers awarded $7.2m in NHMRC grants for health research
15 Sep 2021

MIA researchers awarded $7.2m in NHMRC grants for health research

Three MIA researchers at University of Sydney received grants to further their important melanoma research.

Tags: melanoma
Amie St Clair Ball in Wagga postponed for a third time
06 Sep 2021

Amie St Clair Ball in Wagga postponed for a third time

COVID restrictions continue to impact fundraising for melanoma services in Riverina.

Honouring Ben's life by supporting the next generation of melanoma researchers
30 Aug 2021

Honouring Ben's life by supporting the next generation of melanoma researchers

Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.

MIA's annual Research Retreat 2021
20 Aug 2021

MIA's annual Research Retreat 2021

More than 150 clinicians, researchers and MIA staff gathered online to share research highlights.

Understanding the needs of Stage III melanoma patients when choosing treatments.
28 Jul 2021

Understanding the needs of Stage III melanoma patients when choosing treatments.

Independent researchers at The University of Sydney are seeking patient feedback.

Community Fundraising Wrap Up Apr-June 2021
21 Jul 2021

Community Fundraising Wrap Up Apr-June 2021

A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.

Tags: melanoma
Patients paying it forward
19 Jul 2021

Patients paying it forward

Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients. 

Tags: melanoma
Research boost to improve outcomes for melanoma patients
15 Jul 2021

Research boost to improve outcomes for melanoma patients

MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.

Tags: melanoma
Amie St Clair 10th Annual Ball
25 Jun 2022

Amie St Clair 10th Annual Ball

Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!   

Riverina Melanoma Ride
31 Mar - 07 Apr 2022

Riverina Melanoma Ride

Postponed to early 2022. Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!

Melanoma Clinical Trial opens in Wagga
23 Jun 2021

Melanoma Clinical Trial to open in Wagga

Riverina patients gain access to potentially life saving immunotherapy treatment close to home.

Tags: melanoma
Queen's Birthday Honour for Professor Richard Scolyer
13 Jun 2021

 Queen's Birthday Honour for Professor Richard Scolyer

MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia. 

Tags: melanoma
Sharing our research on the global stage at 2021 ASCO Annual Meeting
07 Jun 2021

Sharing our research on the global stage at 2021 ASCO Annual Meeting

Research from MIA was once again in the spotlight as findings were shared at the virtual ASCO21. 

Tags: melanoma
Australian researchers lead world in successful trial of new cancer treatment
03 Jun 2021

Australian researchers lead world in successful trial of new cancer treatment.

In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.

Tags: melanoma
Thank you doesn't seem enough for our melanoma nurses.
28 May 2021

Thank you doesn't seem enough for our melanoma nurses.

Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.

Tags: melanoma